Telomir Pharmaceuticals (NASDAQ: TELO) reported new research findings from The Ohio State University College of Veterinary Medicine demonstrating that its lead drug candidate, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma as a model for human disease.
Osteosarcoma is a primary bone cancer that affects both humans and dogs, with canine cases often serving as valuable translational models due to similarities in disease progression and biology. The finding that Telomir-Zn inhibits growth in both human and canine cell lines at comparable low concentrations suggests a potential cross-species efficacy that could accelerate development. Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma, offering a dual-benefit approach that is increasingly recognized in oncology research.
Despite the promising osteosarcoma data, Telomir's immediate focus remains its triple-negative breast cancer (TNBC) program. The company is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic TNBC. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting epigenetic and metabolic pathways implicated in cancer. The IND clearance for TNBC marks a significant milestone for the clinical-stage biotechnology company, and the additional osteosarcoma findings may broaden the therapeutic potential of Telomir-Zn.
The implications of these findings are twofold. First, they provide a rationale for further preclinical and clinical development in osteosarcoma, a disease with limited treatment options and poor outcomes in both humans and dogs. If Telomir-Zn proves effective in vivo, it could offer a new therapeutic avenue for a rare and aggressive cancer. Second, the use of canine osteosarcoma as a translational model could expedite the drug's path to human trials, as data from veterinary studies can inform human trial design and dosing. This approach aligns with the growing interest in comparative oncology, where naturally occurring cancers in pets are used to study novel therapies.
For investors, the news highlights Telomir's expanding pipeline beyond its lead TNBC program. While the company's near-term value is tied to the success of the TNBC trial, the osteosarcoma data suggest additional opportunities that could enhance the company's long-term potential. However, it is important to note that these are early-stage in vitro results, and further studies are needed to confirm efficacy and safety in living organisms. The company's discussions with Ohio State and its assessment of next steps indicate a strategic effort to advance the program, but timelines and outcomes remain uncertain.
To view the full press release, visit https://nnw.fm/laeGH. For more information about Telomir Pharmaceuticals, please visit their newsroom at https://nnw.fm/TELO.
